EFEPA Offices

Epilepsy Foundation Eastern Pennsylvania

919 Walnut Street, Suite 700

Philadelphia, PA 19107-5237

Main Number: (215) 629-5003

PA Toll Free: (800) 887-7165

FAX: (215) 629-4997
efepa@efepa.org


Wyoming Valley Office
71 N. Franklin St
Kirby Health Center
Wilkes Barre, PA 18701
epilepsywv@efepa.org
(570) 592-1150

Lehigh Valley
Allentown, PA
lv@efepa.org
(610) 737-0613

Lancaster County
Lancaster, PA
kmichnya@efepa.org
(215) 629-5003 x104
Hours: 8:30 am - 4:30 pm, Monday - Friday

Resources for Women

The EFEPA holds women’s conference…………. (link to women’s conference)
Exchange Presentation
Childcare
Bone Health


Epilepsy Medication

/Epilepsy Medication
2April, 2014

Sign the Epilepsy Research and Medical Marijuana Petition!

By |April 2nd, 2014|Advocacy, Awareness, Education, Epilepsy Medication, Legislative, Treatment, Uncategorized|1 Comment

 

The Epilepsy Foundation of America has started a petition on the White House website. We need your help!  We are calling on the President and the Drug Enforcement Administration to reschedule marijuana to a lower level under the controlled substances act.  The Foundation supports this change to benefit greater access to […]

11January, 2012

ONFI (clobazam) Tablets now Available in the U.S. at Pharmacies

By |January 11th, 2012|Epilepsy Medication, Treatment, Uncategorized|0 Comments

DEERFIELD, Ill.–(BUSINESS WIRE)–Lundbeck announced today that ONFI Tablets are now available for prescribing in the United States. The FDA recently approved ONFI for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients […]

19May, 2011

Drug Shortage Alert

By |May 19th, 2011|Epilepsy Medication|2 Comments

Drug Shortage Alert: Pfizer Announces DILANTIN® 30 mg (Extended Phenytoin Sodium Capsules, USP) Shortage

The Epilepsy Foundation has learned that Pfizer is contacting health care professionals, including pharmacists, about a shortage of DILANTIN 30 mg. According to Pfizer, this product shortage is due to a manufacturing issue and not the result of any performance or safety […]